TICKERNERD
Menu
KURAKURAHealthcare · Biotechnology

KURA Stock Forecast: Kura Oncology, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$9.19
+2.00% on the day

The 15 Wall Street analysts covering Kura Oncology, Inc. hold a median 12-month price target of $28 — +204.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$815.8M
Ticker Nerd rank
71 / 100
Median analyst target
$28
Analysts covering
15
Total return, dividends reinvested
1W
−9.5%
1M
−17.2%
YTD
−11.5%
1Y
+52.7%
From 52W high
−24.3%
From 52W low
+65.9%
$6
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KURA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kura Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
93
Momentum
78
Value
71
Volatility
70
Revisions
68
Quality
60
Size
47
Issuance
28
Growth
22

Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own Kura Oncology, Inc. — and when they’d sell — is the membership.

Wall Street

KURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26KURAHigh $76Median $28Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $15Median $28High $76

The green dot is the last close — the median target sits +204.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 July 2026WedbushReiteratesOutperform$36
15 June 2026CitizensReiteratesMarket Outperform$24
15 June 2026CitizensReiteratesMarket Outperform—
14 Apr 2026Lake StreetInitiatesBuy—
24 Mar 2026MizuhoMaintainsOutperform—
13 Mar 2026UBSMaintainsBuy—
6 Mar 2026WedbushMaintainsOutperform—
13 Jan 2026HC Wainwright & Co.ReiteratesBuy—
13 Jan 2026Leerink PartnersMaintainsOutperform—
24 Nov 2025BarclaysMaintainsOverweight—
14 Nov 2025UBSMaintainsBuy—
14 Nov 2025WedbushMaintainsOutperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
20 Oct 2025JMP SecuritiesReiteratesMarket Outperform—
30 Sept 2025HC Wainwright & Co.ReiteratesBuy—
4 Sept 2025GuggenheimInitiatesNeutral—
11 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
26 June 2025Cantor FitzgeraldReiteratesOverweight—
20 June 2025WedbushReiteratesOutperform—
4 June 2025JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

KURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Kura Oncology, Inc. (KURA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.9×

Cheaper than 87% of US stocks

Price / sales
11.4×

Cheaper than 13% of US stocks

Price / book
7.6×

Cheaper than 14% of US stocks

EV / EBITDA
−0.8×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
29.5%

Higher than 79% of US stocks

Earnings growth (YoY)
29.5%

Higher than 68% of US stocks

Gross margin
98.6%

Higher than 99% of US stocks

Operating margin
−431.5%

Higher than 8% of US stocks

Net margin
99.9%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−124.7%

Higher than 11% of US stocks

Return on assets
−28.4%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KURA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KURAKura Oncology, Inc.$815.8M
71
SLDBSolid Biosciences, Inc.$793.0M
30
ANNXAnnexon, Inc.$817.6M
46
GERNGeron Corp.$826.3M
66
OMEROmeros Corp.$839.5M
69
TBPHTheravance Biopharma, Inc.$849.1M
99
DSGNDesign Therapeutics, Inc.$751.2M
53
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KURA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest KURA news & analysis

Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma Transcript

Seeking Alpha · 27 July 2026neutral

Kura Oncology discussed updated results from the FIT 001 trial evaluating darlifarnib in combination with cabozantinib for the treatment of renal cell carcinoma, as covered in a Seeking Alpha transcript.

Why it matters — The update provides investors and analysts with the latest clinical data on a key pipeline candidate in a major oncology indication.

Kura Oncology Reports 50% Response Rate in RCC Combination Study

MarketBeat · 27 July 2026positive

Kura Oncology presented updated Phase 1 FIT-001 trial results showing a 50% response rate for darlifarnib combined with cabozantinib in advanced renal cell carcinoma patients who had progressed after prior treatment including immunotherapy.

Why it matters — The reported 50% response rate suggests potential clinical activity for Kura's lead candidate in a difficult-to-treat RCC population, making this an important early data readout for investors tracking the company's pipeline progress.

Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

GlobeNewsWire · 27 July 2026positive

Kura Oncology reported clinical data at KCRS 2026 showing durable activity of darlifarnib combined with cabozantinib in cabozantinib-naïve patients with locally advanced or metastatic clear cell renal cell carcinoma (ccRCC), with response rates up to 50% and a median progression-free survival of 13 months across evaluated dose levels.

Why it matters — The results suggest the combination therapy may offer a promising treatment option for pre-treated ccRCC patients who have not previously received cabozantinib, potentially expanding Kura's oncology pipeline.

FAQ

Frequently asked questions about KURA stock

What is the KURA stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Kura Oncology, Inc. have a median 12-month price target of $28, with estimates ranging from $15 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KURA stock a buy right now?

Of the 15 analysts covering Kura Oncology, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kura Oncology, Inc. 71 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KURA?

As at 1 Aug 2026, Kura Oncology, Inc. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).

Will KURA stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +204.7% from the last close, and Ticker Nerd's factor model ranks Kura Oncology, Inc. 71 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KURA stock forecast for 2030?

No analyst covering Kura Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $76 over the next 12 months.

How has KURA stock performed over the past year?

Kura Oncology, Inc. returned +52.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kura Oncology, Inc. do?

Kura Oncology Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of precision medicines for cancer treatment.

What is the latest news on KURA?

The most recent item we track (Seeking Alpha, 27 July 2026): "Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma Transcript". Kura Oncology discussed updated results from the FIT 001 trial evaluating darlifarnib in combination with cabozantinib for the treatment of renal cell carcinoma, as covered in a Seeking Alpha transcript.

Company

About Kura Oncology, Inc.

Kura Oncology Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of precision medicines for cancer treatment. It specializes in novel therapies that selectively target cancer cells, addressing areas with significant unmet medical needs such as HRAS mutant solid tumors, chronic myelomonocytic leukemia, MAPK pathway tumors, and acute leukemias. The company's pipeline features Tipifarnib, a farnesyl transferase inhibitor; KO-947, an ERK inhibitor; and KO-539, a Menin-MLL inhibitor, alongside approved products like Komzifti (ziftomenib) for specific leukemias. Kura Oncology Inc. advances precision oncology by developing targeted treatments that aim to improve patient outcomes in oncology. Founded in 2014 and headquartered in San Diego, California, it operates in the biopharmaceutical sector, contributing to innovative cancer care through its clinical-stage programs.

CEO Dr. Troy Edward Wilson J.D., Ph.D. · 260 employees · United States · https://kuraoncology.com